urologytimes1mnd
Efficacy of sildenafil cream for FSAD maintained across patient subgroups
Age, race, and hormonal contraceptive use did not significantly impact the efficacy of sildenafil cream, 3.6%, in female sexual arousal disorder. Data from a post-hoc analysis of the phase 2b RESPOND ...
Investing1mnd
Daré Bioscience start fase 3-studie voor behandeling van FSAD
SAN DIEGO - Daré Bioscience, Inc. (NASDAQ: DARE) heeft in samenwerking met Strategic Science & Technologies, LLC aangekondigd dat ze binnenkort een fase 3-klinische studie zullen starten met ...
Business Insider1mnd
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first FDA approval for FSAD. Market research estimates ...
BioSpace1mnd
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
FSAD is clinically analogous to erectile dysfunction in men. To date, there are no FDA-approved pharmacological treatments for FSAD; Daré’s Sildenafil Cream has the potential to receive the first FDA ...
Nasdaq1mnd
Daré Bioscience Initiates Phase 3 Study for Sildenafil Cream as Potential First FDA-Approved Treatment for Female Sexual Arousal Disorder
Daré Bioscience, in collaboration with Strategic Science & Technologies, announced plans for a Phase 3 clinical study of Sildenafil Cream, 3.6%, aimed at treating female sexual arousal disorder ...
The Globe and Mail1mnd
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
Detailed price information for Dare Bioscience Inc (DARE-Q) from The Globe and Mail including charting and trades.
ADVFN14d
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)
DARE Dare Bioscience Inc Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) ...